Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 20, Issue 6, Pages 583-592Publisher
TAYLOR & FRANCIS AS
DOI: 10.1080/14737159.2020.1702521
Keywords
Site-agnostic; tumor-agnostic; companion diagnostics; basket trial; personalized medicine; larotrectinib; pembrolizumab; entrectinib; AMG-510; LOXO-195
Categories
Ask authors/readers for more resources
Introduction: Advances within molecular diagnostics have enabled us to identify a number of oncogenic drivers across different cancers. Many cancers can now be divided into subgroups based on molecular characteristics, and an increasing number of targeted anticancer drugs have been developed together with a predictive biomarker assay using the drug-diagnostic codevelopment model. With the recent approval of entrectinib, larotrectinib, and pembrolizumab for site-agnostic indications, biomarker-guided drug development has entered into a new phase. Areas covered: The review focuses on the general principles of drug-diagnostic codevelopment, especially basket trials and site-agnostic drug development. Special attention is paid to entrectinib, larotrectinib, and pembrolizumab. Expert opinion: The recent approval of entrectinib, larotrectinib, and pembrolizumab must be regarded as a paradigm shift in biomarker-guided oncology drug development. For a site-agnostic indication, it is important to have in mind the central role of the companion diagnostic (CDx), as the assay defines the 'disease' and the patient population to be treated. A number of site-agnostic drugs are currently in development and here, it is important that CDx assay development is given high priority, so an analytical and clinical validated assay is available at the time of drug approval.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available